December 27, 2018

Stemline: A Prospective Bio-tech

Stemline Therapeutics just got FDA approval for its flagship product, Elzonris which will begin selling in 2019.  As a result, analysts have begun raising their targets.  Piper Jarray has a $30 price target.  The company is small and not profitable....yet. 

Daseke Fairly Valued at $10 a Share

If you can stand the volatility of a small cap, this analyst states that Daseke is worth $10 a share.  The owner and CEO has recently bought shares, which is also a good sign. 

December 21, 2018

Skechers is Cheap

The Fool and Zacks indicate that shares of Skechers are cheap.  Tarifs may be one of the reasons why the stock has been down lately as international growth is one of the revenue sources the company is relying on.   

December 10, 2018

BIP: Growth and Value

The Fool sees both growth and value in Brookfield Infrastructure Partners.

December 3, 2018

On Alta Mesa Resources

Goldman Sachs is out with a call on Alta Mesa Resources, with a $6.50 price target.  Shares are currently trading around $1.75.